Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-10

Study Completion Date

2025-02-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aim of this study will evaluate the safety, tolerability and preliminary efficacy of chimeric antigen receptor T cells (CAR-T) targeting Igβ targets in patients with Igβ-positive refractory relapsed non-Hodgkin's lymphoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

NCT05013372

T-cell Non-Hodgkin's Lymphoma

UNKNOWN EARLY_PHASE1

Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma

NCT06381830

Lymphoma, B-Cell Autologous Stem Cell Transplantation

RECRUITING PHASE2

Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies

NCT05127135

T-Acute Lymphoblastic Leukemia T-cell Non-Hodgkin Lymphoma T-cell Acute Lymphoblastic Lymphoma

UNKNOWN PHASE1

Safety and Efficacy of CD207 Targeted CAR-T Cell Therapy in Patients With R/R Langerhans Cell Histiocytosis

NCT05477446

Langerhans Cell Histiocytosis

UNKNOWN PHASE1

Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic Lymphoma

NCT05745181

Acute T-lymphoblastic Leukemia Acute T-lymphoblastic Lymphoma

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Non-Hodgkin's lymphoma is a group of malignant neoplasms of the lymphatic system originating from B or T cells, of which 60-70% of patients have B-cell-derived lymphoma (B-NHL). Although rituximab in combination with chemotherapy has significantly improved the prognosis of B-cell lymphoma, some patients still have primary resistance or relapse. In recent years, breakthroughs have been made in the treatment of B-cell tumors with Chimeric Antigen Receptor-Modified T Cells (CART), the investigators therefore constructed CAR-T cells targeting Igβ to investigate the safety and efficacy of CAR-T cells with this target for the treatment of r/r B-NHL.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets

Chimeric antigen receptor T cells targeting Igβ targets (CAR-T)

Group Type EXPERIMENTAL

Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets

Intervention Type DRUG

1. Dose escalation studies:3 dose groups in total: expect 3-6 cases in each group, and dose set at 1×106/kg，3×106/kg，6×106/kg.
2. Dose extension study:3 cases (1 dose group).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets

1. Dose escalation studies:3 dose groups in total: expect 3-6 cases in each group, and dose set at 1×106/kg，3×106/kg，6×106/kg.
2. Dose extension study:3 cases (1 dose group).

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Chimeric antigen receptor-modified T (CAR-T) cell therapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Voluntary signing of informed consent and good compliance.
2. Age ≥ 6 years.
3. Previously treated with 2 or more lines of therapy.
4. Has a measurable target lesion.
5. ECOG 0-1#.
6. Have appropriate organ function, subject to the following criteria (except for abnormal liver function due to tumor infiltration): AST≤3 times upper limit of normal#ALT≤3 times upper limit of normal# TB≤2 times ULN, unless combined with Gilbert's syndrome #Patients with Gilbert's syndrome with TB≤ 3 times ULN and DB≤ 1.5 times ULN can be include # Scr ≤1.5 times ULN or CCr≥60 ml/min# Lung function≤Level 1; dyspnea(CTCAE v5.0),and blood oxygen saturation without oxygen absorption\> 91%# INR≤1.5 times ULN# aPTT≤1.5 times ULN.
7. negative blood/urine pregnancy test in women of childbearing age within 7 days prior to cell infusion, and any male and female patients of childbearing potential must agree to use an effective method of contraception throughout the study and for at least six months after the study treatment is administered.
8. Pass the T-cell amplification test.
9. Have adequate venous access to single or venous blood and no other contraindications to leukocyte isolation.
10. Estimated survival time ≥3 months.

Exclusion Criteria

1. Prior malignancy (other than Relapsed Refractory B-cell Non-Hodgkin's Lymphoma), except for cured malignant tumors with no active lesions for 3 years; Adequate treatment of inactive lesions in non-melanoma skin cancer, malignant tonsilloma or carcinoma in situ.
2. Have used immunosuppressants or hormones within 2 weeks prior to signing informed consent, or plan to have to use immunosuppressants or high-dose hormones (e.g. prednisone \>15mg) after signing informed consent, specifically systemic treatment, excluding treatment with topical or inhaled corticosteroids.
3. The presence of bacterial, fungal, viral, mycoplasma or other types of infection that, in the judgment of the investigator, are difficult to control.
4. HIV, Syphilis or COVID-19 infection.
5. Active hepatitis B or active hepatitis C.
6. Previous or current CNS disease other than this disease, such as seizures, cerebrovascular ischaemia/hemorrhage, dementia, cerebellar disease or any CNS-related autoimmune disease.
7. A history of cardiac angioplasty or stent placement within 12 months prior to signing the informed consent form, or a history of myocardial infarction, unstable angina or other clinically significant heart disease.
8. Patients with primary immunodeficiency.
9. Have had a severe tachyphylaxis to any of the drugs to be used in this study.
10. Live vaccination within 6 weeks prior to screening.
11. Pregnant or breasting-feeding women.
12. Active autoimmune diseases.
13. Active acute or chronic graft-versus-host disease (GVHD) at the time of signing the informed consent form.
14. Received an allogeneic hematopoietic stem cell transplant within 6 months prior to signing the informed consent form.
15. Participated in an investigational clinical trial of any other drug within 30 days prior to signing the informed consent form.
16. Conditions deemed by the researcher to be inappropriate for participation in this clinical trial.

Minimum Eligible Age

6 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No